These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28173960)

  • 1. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
    Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
    Huijts SM; van Werkhoven CH; Bolkenbaas M; Grobbee DE; Bonten MJM
    Vaccine; 2017 Aug; 35(34):4444-4449. PubMed ID: 28410813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R; Webber C
    Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
    Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
    N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
    van Werkhoven CH; Bonten MJ
    Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
    van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM
    Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
    Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy.
    Fletcher MA; Schmoele-Thoma B; Vojicic J; Daigle D; Paradiso PR; Del Carmen Morales G
    Expert Rev Vaccines; 2024; 23(1):944-957. PubMed ID: 39279631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial.
    Lucero MG; Nohynek H; Williams G; Tallo V; Simões EA; Lupisan S; Sanvictores D; Forsyth S; Puumalainen T; Ugpo J; Lechago M; de Campo M; Abucejo-Ladesma E; Sombrero L; Nissinen A; Soininen A; Ruutu P; Riley I; Mäkelä HP
    Pediatr Infect Dis J; 2009 Jun; 28(6):455-62. PubMed ID: 19483514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
    Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
    Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
    McLaughlin JM; Jiang Q; Gessner BD; Swerdlow DL; Sings HL; Isturiz RE; Jodar L
    Vaccine; 2019 Oct; 37(43):6310-6316. PubMed ID: 31522807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
    Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Neuzil KM; O'Brien KL; Wunderink RG; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Sep; 37(38):5777-5787. PubMed ID: 29861177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
    LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Plosker GL
    Drugs; 2015 Sep; 75(13):1535-46. PubMed ID: 26242768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
    BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
    McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
    Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.